Ask AI
EBC IDST
Interactive Decision Support Tool: Selecting Systemic Therapy for Early Breast Cancer

Released: August 07, 2026

About This Tool & Disclaimer

Interactive Decision Support Tool: Selecting Systemic Therapy for Early Breast Cancer

Decera Clinical Education, LLC, is grateful to Shipra Gandhi, MD, MS; Tanya Gupta, MD; Reshma L. Mahtani, DO; Erica L. Mayer, MD, MPH; and Laura Spring, MD; who provided expert guidance, knowledge, and support in the development of this Interactive Decision Support Tool.

Note: The current tool was created in July 2027 and reflects the guidelines available at that time.

The goal of the tool is to educate healthcare professionals on making optimal management choices for patients with early-stage HR-positive/HER2-negative, HER2-positive, and triple-negative breast cancer (TNBC).

A series of questions allows the participant to select individual patient characteristics that are necessary to consider when making management choices. These characteristics include disease stage, tumor size, risk category, lymph node and biomarker status (BRCA1 and/or BRCA2), as well as present comorbidities that might inform treatment selection or modifications.

It should be noted that these are not exclusive characteristics when selecting optimal treatment for patients with early-stage breast cancer. Other considerations that are not included in this tool, such as different types of surgical procedures, local and/or systemic treatments for metastatic disease, and alternative non-interventional approaches should also be considered, when appropriate for making management decisions.

This tool assumes we have a “standard” patient with early-stage HR-positive/HER2-negative, HER2-positive, or TNBC but with no additional features or specific comorbidities that would affect treatment choice other than those described when entering the patient details. Based on the characteristics entered, the tool will display guideline and expert recommendations for that specific patient case.

The additional considerations text will include discussions on available options for resectable disease and link(s) to other tools available for metastatic breast cancer.


This interactive decision support tool focuses exclusively on resectable or unresectable nonmetastatic early-stage breast cancer. follow these links for more information on available interactive decision support tools for metastatic breast cancer: HR-positive/HER2-negative and HER2-positive breast cancer.


For additional content and resources on the management of patients with early-stage breast cancer, access online educational modules on HER2-positive/HER2-low EBC, HR-positive/HER2-negative EBC, and early-stage TNBC authored by Laura Spring, MD, Tanya Gupta, MD, and Kristen D. Whitaker, MD, MS, respectively.


This program is supported by an educational grant from AstraZeneca and Daiichi Sankyo, Inc.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Shipra Gandhi, MD, MS: consultant/advisor/speaker: AstraZeneca, Genentech, Hologic, MGH Life Sciences, Novartis, Roche, Stemline.

Tanya Gupta, MD: advisor: AstraZeneca, Biotheranostics, Gilead, Merck, Novartis, Pfizer.

Reshma L. Mahtani, DO: consultant/advisor/speaker: Agendia, AstraZeneca, Arvinas, Bicycle Therapeutics, Celcuity, Daiichi Sankyo, Genentech, Gilead, Hologic, Lilly, Novartis, Pfizer, Puma, Stemline.

Erica L. Mayer, MD, MPH: consultant/advisor/speaker: Aktis, AstraZeneca, Genentech, Lilly, Novartis.

Laura Spring, MD: consultant/advisor: AstraZeneca, Daiichi Sankyo, Gilead, Lilly, Novartis, Pfizer, Precede, Seagen; researcher (paid to institution): AstraZeneca, Genentech, Gilead, Greenwich Life Sciences, Lilly, Merck.

©2026 Decera Clinical Education, LLC. All rights reserved.

Access to and use of this Interactive Decision Support Tool titled, “Interactive Decision Support Tool: Selecting Systemic Therapy for Early Breast Cancer” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate healthcare professionals on making optimal management choices for patients with early-stage HR-positive/HER2-negative, HER2-positive, and triple-negative breast cancer (TNBC). The information provided is based on guideline recommendations and expert guidance of Shipra Gandhi, MD, MS; Tanya Gupta, MD; Reshma L. Mahtani, DO; Erica L. Mayer, MD, MPH; and Laura Spring, MD. The material published by Decera Clinical Education reflects the views of the reviewers or authors of the Decera Clinical Education material, not those of Decera Clinical Education, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Interactive Decision Support Tool: Selecting Systemic Therapy for Early Breast Cancer” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Decera Clinical Education provides this information on an as-is basis. This disclaimer applies to all material published by Decera Clinical Education, including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

©2026 Decera Clinical Education, LLC. All rights reserved.

Program Content